RNAC vs WAT · P/E 2.1, rev $38.9M vs P/E 32, rev $3.17B
Cartesian Therapeutics Inc. (RNAC) versus Waters Corporation (WAT) — a side-by-side from cached financials, not a winner call.
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
Waters Corporation (WAT) is a diagnostics & research company listed on US.
Latest reported RNAC revenue for 2024-12-31 was $38.9M. Net income was -$77.4M. Revenue was up 49.6% from 2023-12-31 to 2024-12-31. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Latest reported WAT revenue for 2025-12-31 was $3.17B. Net income was $642.6M. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
RNAC currently screens at market cap $290.9M and trailing P/E 2.1. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
Not investment advice. Open the RNAC and WAT stock pages for the full models.
Not investment advice.